A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs CD 101 (Primary) ; Caspofungin; Fluconazole
  • Indications Candidaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Cidara Therapeutics
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Nov 2017.
    • 11 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Oct 2017.
    • 21 Feb 2017 According to a Cidara Therapeutics media release, results from this trial are expected during the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top